CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...